Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence
Hepatocellular carcinoma (HCC) is a leading cause of new cancer diagnoses in the United States, with an incidence that is expected to rise. The etiology of HCC is varied and can lead to differences between patients in terms of presentation and natural history. Subsequently, physicians treating these...
Main Authors: | Pierre M. Gholam, Renuka Iyer, Matthew S. Johnson |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/6/873 |
Similar Items
-
Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines
by: Soumya Jogi, et al.
Published: (2020-12-01) -
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials
by: Casadei Gardini A, et al.
Published: (2018-10-01) -
Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy
by: Bishay VL, et al.
Published: (2014-11-01) -
Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis
by: Fausto Meriggi, et al.
Published: (2021-02-01) -
Long-term survival with transarterial chemoembolization and radioembolization in a patient with cancers of unknown primary
by: Aktas G, et al.
Published: (2018-04-01)